Wire · opportunities
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
Phase 3 trial HERIZON-GEA-01 results show Ziihera (zanidatamab-hrii) with chemotherapy significantly improves overall survival compared to trastuzumab plus chemotherapy as first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma. The regimen with added tislelizumab also shows enhanced survival benefit, supporting Ziihera as the new standard of care with recent FDA approval in the US.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 25 Aug 2026 and 31 Aug 2026.
◆ ◆ The Wire takeaway
You must pivot fast to include Ziihera in treatment protocols as it displaces trastuzumab for HER2+ gastroesophageal cancer in the US. The FDA approval opens access and sets a new survival benchmark, impacting drug positioning and clinical adoption this quarter.
◆ Coverage
10 sources · first reported 25 Aug 2026 · latest 31 Aug 2026
◆ Topics